Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint

In conclusion, there was a concordance between Ki-67 and MammaPrint risk stratification of HR+ EIBC and no concordance with the EndoPredict molecular signature, but a positive association with the given percentage of recurrence and the median Ki-67 index as the cutoff at our center. Cost-effectiveness analyses of these tests in developing countries are required; until then, the use of Ki-67 appears reasonable to aid clinical decisions, together with the other established clinicopathological variables.PMID:35949891 | PMC:PMC9353786 | DOI:10.3892/mco.2022.2565
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research